Home / Health / FDA Approves Alfapump for Liver Cirrhosis Relief

FDA Approves Alfapump for Liver Cirrhosis Relief

Summary

  • First alfapump implantation occurred at Mount Sinai Hospital in the U.S.
  • The device automatically removes ascites fluid for natural elimination.
  • It aims to significantly improve quality of life for patients.
FDA Approves Alfapump for Liver Cirrhosis Relief

A significant advancement in medical technology, the alfapump, has received FDA approval for the treatment of ascites related to liver cirrhosis in the United States. This innovative device was first implanted at Mount Sinai Hospital, marking a new era for patients suffering from this condition.

The alfapump offers a revolutionary approach by automatically removing ascitic fluid from the abdomen. This fluid is then directed to the bladder for natural elimination through urination, effectively ending the need for repeated and invasive drainage procedures. Patients can now anticipate a life free from the burden of frequent interventions.

Dr. Rahul Patel highlighted the alfapump as a transformative technology, emphasizing its potential to enhance patient quality of life and decrease hospitalizations. This breakthrough offers a less invasive and more continuous management of ascites, providing much-needed relief and hope for those affected by this challenging medical condition.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The alfapump is approved by the FDA for the treatment of recurrent or refractory ascites due to liver cirrhosis.
The alfapump automatically removes ascitic fluid from the abdomen into the bladder for natural elimination via urination.
The first alfapump implantation in the U.S. occurred at Mount Sinai Hospital.

Read more news on